
Home » Sotagliflozin Reduces AIC in Phase III Trial in Type 1 Diabetes
Sotagliflozin Reduces AIC in Phase III Trial in Type 1 Diabetes
September 19, 2016
Lexicon Pharmaceuticals announced that a Phase III clinical trial of sotagliflozin met its primary endpoint, demonstrating a significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin.
Lexicon is conducting a similar Phase III trial in Europe, which is expected to report top-line results by the end of the year. A third Phase III trial is underway globally, studying approximately 1,400 patients treated with sotagliflozin 400 mg once daily or placebo on a background of any insulin therapy, but without insulin optimization prior to randomization.
Lexicon previously granted Sanofi a worldwide license to develop sotagliflozin, and Sanofi is planning to initiate Phase III clinical trials in type 2 diabetes by the end of the year.
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr